Biotech Values

[iwfal]

Satraplatin - If the survival data are the focal point of the ODAC then I would guess the submitters are going to have problem - because the survival data appear to be trending to an HR that would not be stat sig.

Note that I haven't done any detailed analyses and know very little about the trial history of this drug - so I am not competent to speak to the general review. I am instead only making a micro observation - extrapolating from the fact that the current p value is about 0.3 and more than 1/2 of the deaths have occurred.

Clark